Prof. Dr. Hüseyin ABALI
Başkent Üniversitesi İç Hastalıkları Tıbbi Onkoloji Bilim Dalı Öğretim Üyesi
…
Hüseyin ABALI1970 yılında Mersin’e bağlı Arslanköy kasabasında doğdu. İlköğretiminin büyük bölümünü burada yaptıktan sonra son lise 3. sınıfı Mersin Tevfik Sırrı Gür Lisesi’nde okudu. 1988-1995 yıllarında Hacettepe Üniversitesi Tıp Fakültesi (İngilizce Grup) tıp eğitimini aldıktan sonra, 1995-2000 yılları arasında aynı kurumda İç Hastalıkları uzmanlık eğitimi ve 2000-2003 yılları Tıbbi Onkoloji yan dal eğitimini aldı. 2006 Yılında “İç Hastalıkları Tıbbi Onkoloji” alanında Doçent doktor ve 2011 yılında Prof doktor oldu. ...[Devamı...]
2003-2006 yıllarında T.C. Sağlık Bakanlığı Ankara Numune Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniğinde başasistan olarak çalıştı. Bu kurumda aynı zamanda dönemde Kemik İliği Nakil Ünitesi’nde de çalışmaları oldu. 2006-2008 yıllarında Mersin Üniversitesi Tıp Fakültesi İç Hastalıkları Tıbbi Onkoloji Bölümü’nde olarak çalıştı. 2008-2014 arasında Başkent Üniversitesi İç Hastalıkları Tıbbi Onkoloji BD’da öğretim üyesi olarak Başkent Üniversitesi Tıp Fakültesi Adana Uygulama ve Araştırma Merkezi Tıbbi Onkoloji Bölümü’nde çalıştı. Halen Acıbadem Adana Hastanesi Tıbbi Onkoloji Kliniği'nde çalışmaktadır.
ASCO (American Society of Clinical Oncology), ESMO (European Society of Medical Oncology), MASCC (Multinational Association for Supportive Care in Cancer), ISO (International Society of Oral Oncology), ENETS (European Neuroendocrin Tumor Society), GMTF (Global Melanoma Task Force) ve TOD (Tıbbi Onkoloji Derneği) ve TOG (Türk Onkoloji Grubu) üyesidir. TOD’un Güney ve Güney Doğu Bölge Temsilciliğini yürütmektedir.
USMLE (United States Medical Licensing Examination) Sertifikasına sahip olup, 2009 yılında Harvard Medical School’da “visiting physician” olarak bulunmuştur. Klinik araştırmalar ve iyi klinik uygulamalar konusunda yurtdışında eğitim almıştır. Ulusal ve uluslararası çalışmalarda göreve almaktadır.
Ulusal toplantılarda en iyi proje ve bildiri ödülleri bulunmaktadır. Ulusal kongrelere düzenleme kurulu ve konuşmacı olarak katkıda bulunmaktadır.
Uluslararası hakemli dergilerde 70’ın üzerinde yayını, yurtdışında yayınlanmış 2 kitap bölümü, yurt içinde 2 kitap bölümü ve 1 yardımcı editörlüğü bulunmaktadır. MASCC bulantı kusma tedavi kılavuzunu Türkçeye çevirmiştir. Ulusal ve uluslar arası hakemli dergilerde hakem olarak görev yapmaktadır. Çalışmalarına 250 kez atıfta bulunulmuştur.
Tavsiye ve Teşekkürler
Gülten
► Profesyonel Hizmet Alan Hasta
29.Temmuz.2012
TavsiyeNo: 52760
Hacer K.
► Profesyonel Hizmet Alan Hasta
8.Eylül.2009
TavsiyeNo: 26280
Nagihan K.
15.Haziran.2009
TavsiyeNo: 24106
▪ Doktor ve Diş Hekimi üyelerimize ait ziyaretçi yazılarının içerikleri şu aşamada sadece üyemizin kendisine gösterilmektedir.
Prof.Dr.Hüseyin ABALI'nın Basılı Kitap ve Yayınları
1: Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V,
Scotto N, Osborne S, Fallowfield L; on behalf of the PrefHer Study Group; on
behalf of the PrefHer Study Group. Patients' preferences for subcutaneous
trastuzumab versus conventional intravenous infusion for the adjuvant treatment
of HER2-positive early breast cancer: final analysis of 488 patients in the
international, randomized, two-cohort PrefHer study. Ann Oncol. 2014 Jul 28. pii:
mdu364. [Epub ahead of print] PubMed PMID: 25070545.
2: Taner Sumbul A, Sezer A, Tonyali O, Akif Ozturk M, Abali H, Ozyilkan O. Being
a medical oncologist near the war area. J BUON. 2014 Apr-Jun;19(2):580. PubMed
PMID: 24965429.
3: Muallaoglu S, Disel U, Tekin A, Mertsoylu H, Abali H, Ozyilkan O. Prolonged
use of bevacizumab may cause extensive coronary artery thrombosis. J BUON. 2014...[Devamı...]
Apr-Jun;19(2):578-9. PubMed PMID: 24965427.
4: Sezer A, Sümbül AT, Abalı H, Mertsoylu H, Ozyılkan O. Malignant pleural
mesothelioma: a single-center experience in Turkey. Med Sci Monit. 2014 May
20;20:825-32. doi: 10.12659/MSM.890020. PubMed PMID: 24842043; PubMed Central
PMCID: PMC4038637.
5: Sezer A, Sumbul AT, Abali G, Sumbul Z, Muallaoglu S, Abali H. Can low
molecular weight heparins circumvent the problem of coumadine and chemotherapy
interaction in cancer patients with prosthetic heart valves? Asian Pac J Cancer
Prev. 2014;15(4):1889-90. PubMed PMID: 24641426.
6: Sümbül AT, Dişel U, Sezgin N, Sezer A, Köse F, Beşen AA, Sümbül Z, Abalı H,
Özyılkan Ö. Can serial monitoring of serum Vascular Endothelial Growth Factor
(VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role
during Bevacizumab treatment? Med Sci Monit. 2014 Mar 15;20:428-33. doi:
10.12659/MSM.889945. PubMed PMID: 24632679; PubMed Central PMCID: PMC3962326.
7: Sezer A, Sumbul AT, Abali H. Is it rational to continue anti-neoplastics with
minimal toxicity even after progression in patients with no other options?
Possibly yes. Asian Pac J Cancer Prev. 2014;15(2):1061-2. PubMed PMID: 24568451.
8: Sümbül AT, Sezer A, Abalı H, Köse F, Gültepe I, Mertsoylu H, Muallaoğlu S,
Ozyılkan O. Neutrophil-to-lymphocyte ratio predicts PSA response, but not
outcomes in patients with castration-resistant prostate cancer treated with
docetaxel. Int Urol Nephrol. 2014 Aug;46(8):1531-5. doi:
10.1007/s11255-014-0664-7. Epub 2014 Feb 13. PubMed PMID: 24526335.
9: Sümbül AT, Sezer A, Kavvasoğlu G, Batmacı CY, Yengil E, Yağız AE, Gültepe I,
Abalı H, Üstün I, Gökçe C. Low serum levels of vitamin D in metastatic cancer
patients: a case-control study. Med Oncol. 2014 Mar;31(3):861. doi:
10.1007/s12032-014-0861-3. Epub 2014 Feb 4. PubMed PMID: 24493144.
10: Ozdemir N, Aksoy S, Sendur MA, Akinci MB, Yazici O, Budakoglu B, Abali H,
Oksuzoglu B, Zengin N. Capecitabine/cisplatin doublet in anthracycline and taxane
pretreated and HER-2 negative metastatic breast carcinoma patients. J BUON. 2013
Oct-Dec;18(4):831-7. PubMed PMID: 24344005.
11: Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter
J, Eggermont AM, Hauschild A, Espinosa E. Who Benefits Most From Adjuvant
Interferon Treatment for Melanoma? Am J Ther. 2013 Oct 30. [Epub ahead of print]
PubMed PMID: 24176884.
12: Odabas H, Ozdemir NY, Ziraman I, Aksoy S, Abali H, Oksuzoglu B, Isik M,
Civelek B, Dede D, Zengin N. Effect of port-care frequency on venous port
catheter-related complications in cancer patients. Int J Clin Oncol. 2014
Aug;19(4):761-6. doi: 10.1007/s10147-013-0609-7. Epub 2013 Aug 27. PubMed PMID:
23978939.
13: Bozkirli E, Bakiner O, Abali H, Andic C, Yapar AF, Kayaselcuk F, Ertorer E. A
case of inoperable malignant insulinoma with resistant hypoglycemia who
experienced the most significant clinical improvement with everolimus. Case Rep
Endocrinol. 2013;2013:636175. doi: 10.1155/2013/636175. Epub 2013 May 8. PubMed
PMID: 23738155; PubMed Central PMCID: PMC3664472.
14: Muallaoglu S, Disel U, Mertsoylu H, Besen A, Karadeniz C, Taner Sumbul A,
Abali H, Ozyilkan O. Acute infusion reactions to chemotherapeutic drugs: a single
institute experience. J BUON. 2013 Jan-Mar;18(1):261-7. PubMed PMID: 23613414.
15: Hayran M, Kilickap S, Elkiran T, Akbulut H, Abali H, Yuce D, Kilic D, Turhal
S. Smoking habits of relatives of patients with cancer: cancer diagnosis in the
family is an important teachable moment for smoking cessation. Asian Pac J Cancer
Prev. 2013;14(1):475-9. PubMed PMID: 23534777.
16: Ata A, Abali H, Yengel E, Arican A. It is not only the empty vials that go
into the garbage can during chemotherapy drugs preparation: a cost analysis of
unused chemotherapy drugs in cancer treatment. J BUON. 2012 Oct-Dec;17(4):781-4.
PubMed PMID: 23335541.
17: Abali H, Sezer A, Oğuzkurt L, Gürel K, Özkan U, Beşen AA, Sümbül AT, Köse F,
Dişel U, Muallaoğlu S, Özyılkan Ö. Which patients with advanced cancer and
biliary obstruction benefit from biliary stenting most? An analysis of prognostic
factors. Support Care Cancer. 2013 Apr;21(4):1131-5. doi:
10.1007/s00520-012-1636-z. Epub 2012 Nov 8. PubMed PMID: 23132146.
18: Bozcuk H, Abali H, Coskun S; Lung Cancer Committee of Turkish Oncology Group.
The correlates of benefit from neoadjuvant chemotherapy before surgery in
non-small-cell lung cancer: a metaregression analysis. World J Surg Oncol. 2012
Aug 9;10(1):161. doi: 10.1186/1477-7819-10-161. PubMed PMID: 22877422; PubMed
Central PMCID: PMC3463432.
19: Abali H. Comments on cytoreductive surgery and intraperitoneal chemotherapy.
Eur J Surg Oncol. 2012 Oct;38(10):1011; author reply 1012. doi:
10.1016/j.ejso.2012.07.005. Epub 2012 Jul 18. PubMed PMID: 22818844.
20: Dişel U, Beşen A, Karadeniz C, Mertsoylu H, Sezer A, Köse F, TanerSümbül A,
Gürkut O, Muallaoğlu S, Abali H, Ozyilkan O. Prevalence of thyroid dysfunction in
untreated cancer patients: a cross-sectional study. Med Oncol. 2012
Dec;29(5):3608-13. doi: 10.1007/s12032-012-0254-4. Epub 2012 May 22. PubMed PMID:
22729367.
21: Esin S, Tarim E, Abali H, Kardes O, Kocer EN, Alkan O. Management of
precursor B-lymphoblastic lymphoma/leukaemia of thoracic spine in a pregnancy
presenting with acute paraplegia. J Obstet Gynaecol. 2012 Jul;32(5):485-6. doi:
10.3109/01443615.2012.683213. PubMed PMID: 22663326.
22: Onal C, Abali H, Koc Z, Kara S. Radiation recall pneumonitis caused by
erlotinib after palliative definitive radiotherapy. Onkologie. 2012;35(4):191-4.
doi: 10.1159/000337616. Epub 2012 Mar 15. PubMed PMID: 22488089.
23: Dişel U, Abalı H, Sümbül AT, Ozyılkan O. Hypertension associated with
angiogoenesis inhibitors: what do oncologists really do in daily routine? A small
survey. J Clin Hypertens (Greenwich). 2011 Nov;13(11):863. doi:
10.1111/j.1751-7176.2011.00526.x. Epub 2011 Aug 24. PubMed PMID: 22051434.
24: Abali H, Ata A, Ozdogan M, Turhal S, Cabuk D, Seyrek E, Senol Coskun H, Arik
Z, Erman M, Celik I. Frequency of comorbid illnesses in cancer patients in
Turkey. J BUON. 2011 Jul-Sep;16(3):557-60. PubMed PMID: 22006766.
25: Kose F, Abali H, Sezer A, Ali Besen A, Taner Sumbul A, Karadeniz C, Disel U,
Ozyilkan U. Patients with advanced cholangiocarcinoma benefit from chemotherapy
if they are fit to receive it: single center experience. J BUON. 2011
Jul-Sep;16(3):469-72. PubMed PMID: 22006752.
26: Odabas H, Ozdemir N, Isik M, Abali H, Oksuzoglu B, Kos T, Civelek B, Babacan
AN, Dogan U, Zengin N. Safety and efficacy of FOLFIRI-bevacizumab for metastatic
colorectal carcinoma as second line treatment. J BUON. 2011 Jul-Sep;16(3):460-3.
PubMed PMID: 22006750.
27: Abali H, Ata A, Gokçe G, Gokçe H. Possible logistic and sociodemographyc
factors on breast cancer screening in Turkey: lessons from a women’s health
project in Mersin province. J Cancer Educ. 2012 Jun;27(2):347-52. doi:
10.1007/s13187-011-0270-7. PubMed PMID: 21976034.
28: Karadeniz C, Köse F, Abali H, Sümbül AT, Oğuzkurt L, Karabacak T, Oberg K.
Severe systemic vasoconstriction starting with acute limb ischemia leading to
death in a patient with well-differentiated pulmonary neuroendocrine carcinoma: a
new paraneoplastic syndrome? Acta Oncol. 2012 Jan;51(1):124-7. doi:
10.3109/0284186X.2011.602115. Epub 2011 Aug 22. PubMed PMID: 21859354.
29: Odabas H, Ozdemir N, Abali H, Oksuzoglu B, Isik M, Uncu D, Cihan S, Seker M,
Zengin N. First-line therapy for metastatic colorectal carcinoma: modified
FOLFOX4 or FOLFIRI-bevacizumab. J BUON. 2011 Apr-Jun;16(2):247-52. PubMed PMID:
21766493.
30: Seyhan EC, Altın S, Cetinkaya E, Sökücü S, Abali H, Buyukpinarbasili N, Fener
N. Prognostic significance of ERCC1 expression in resected non small cell lung
carcinoma. Ann Thorac Cardiovasc Surg. 2011;17(2):110-7. PubMed PMID: 21597406.
31: Kos FT, Uncu D, Ozdemir N, Budakoglu B, Odabaş H, Abali H, Oksuzoglu B, Aksoy
S, Zengin N. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified
docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of
metastatic gastric cancer. Chemotherapy. 2011;57(3):230-5. doi:
10.1159/000327840. Epub 2011 May 18. PubMed PMID: 21597287.
32: Uncu D, Ozdemir NY, Aksoy S, Abali H, Oksuzoglu BC, Budakoglu B, Yildiz R,
Aslan N, Zengin N. Adjuvant bi-weekly combination of cisplatin, infusional
5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with
infusional fluorouracil for high risk operated gastric and gastroesophageal
junction adenocarcinoma. Asian Pac J Cancer Prev. 2010;11(6):1493-7. PubMed PMID:
21338186.
33: Hayran M, Abali H, Kilickap S, Mentes T, Aksoy H, Kemik A, Gokce H, Gokdemir
H, Toplar S, Kaya D, Isbir GG. Socio-demographic parameters in screening for
breast cancer: Lessons from a population-'based women's Health Project held in a
province in Turkey. J BUON. 2010 Oct-Dec;15(4):726-31. PubMed PMID: 21229637.
34: Dişel U, Oztuzcu S, Beşen AA, Karadeniz C, Köse F, Sümbül AT, Sezer A, Nursal
GN, Abalı H, Ozyılkan O. Promising efficacy of sorafenib in a relapsed thymic
carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer. 2011
Jan;71(1):109-12. doi: 10.1016/j.lungcan.2010.09.011. PubMed PMID: 20970876.
35: Kose F, Abali H, Besen A, Disel U, Hayran M. The prevalence of depression in
patients with cancer in Jordan. Support Care Cancer. 2010 Jun;18(6):657-8. doi:
10.1007/s00520-010-0842-9. Epub 2010 Apr 8. PubMed PMID: 20376503.
36: Disel U, Gürkut O, Abali H, Kaleağasi H, Mertsoylu H, Ozyilkan O, Saif MW.
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Cutan Ocul Toxicol. 2010 Jun;29(2):140-2. doi: 10.3109/15569521003699585. PubMed
PMID: 20298142.
37: Abali H, Dişel U, Urün Y, Güllü I, Saif MW. How shall we name the
chemotherapy administration before and after metastasectomy? How about
"M-neoadjuvant" and "M-adjuvant"? Ann Surg Oncol. 2010 Jul;17(7):1970. doi:
10.1245/s10434-010-1011-6. Epub 2010 Mar 9. PubMed PMID: 20217255.
38: Seyhan EC, Altın S, Cetinkaya E, Sökücü S, Abalı H, Buyukpinarbasili N, Fener
N. Prognostic value of epidermal growth factor receptor expression in operable
non-small cell lung carcinoma. Multidiscip Respir Med. 2010 Oct 31;5(5):305-11.
doi: 10.1186/2049-6958-5-5-305. PubMed PMID: 22958707; PubMed Central PMCID:
PMC3463051.
39: Ozcan T, Horoz M, Abali H, Genctoy G, Akcay B, Ozeren M, Kiykim A. Unusual
aortic localization of a malignant epithelial tumor metastasis of unknown origin.
J Cardiovasc Med (Hagerstown). 2009 Jan;10(1):78-80. PubMed PMID: 19708229.
40: Ozdemir NY, Abali H, Oksüzoğlu B, Budakoglu B, Uncu D, Güler T, Odabaşi H,
Zengin N. The efficacy and safety of reduced-dose docetaxel, cisplatin, and
5-fluorouracil in the first-line treatment of advanced stage gastric
adenocarcinoma. Med Oncol. 2010 Sep;27(3):680-4. doi: 10.1007/s12032-009-9268-y.
Epub 2009 Jul 25. PubMed PMID: 19633962.
41: Abali H, Disel U, Köse F, Sezer A, Mertsoylu H. Immediate or delayed
docetaxel: does progression-free survival really reflect two strategies? J Clin
Oncol. 2009 Jun 10;27(17):2889; author reply 2889. doi: 10.1200/JCO.2009.22.3305.
Epub 2009 Apr 27. PubMed PMID: 19398567.
42: Kose F, Abali H, Sezer A, Mertsoylu H, Disel U, Ozyilkan O. Little dose, huge
toxicity: profound hematological toxicity of intrathecal methotrexate. Leuk
Lymphoma. 2009 Feb;50(2):282-3. doi: 10.1080/10428190802603169. PubMed PMID:
19197737.
43: Ozdemir NY, Abali H, Oksüzoğlu B, Budakoğlu B, Akmangit I, Zengin N. It
appears to be safe to start chemotherapy on the day of implantation through
subcutaneous venous port catheters in inpatient setting. Support Care Cancer.
2009 Apr;17(4):399-403. doi: 10.1007/s00520-008-0498-x. Epub 2008 Sep 2. PubMed
PMID: 18762993.
44: Oksuzoglu B, Abali H, Hayran M, Yildirim N, Budakoglu B, Zengin N.
Capecitabine and cisplatin combination is an active and well-tolerated doublet in
the treatment of metastatic breast carcinoma patients pretreated with
anthracycline and taxanes. Chemotherapy. 2008;54(5):352-6. doi:
10.1159/000151630. Epub 2008 Aug 26. PubMed PMID: 18728366.
45: Pamukcuoglu M, Oksuzoglu B, Abali H, Akoglu M, Atalay F, Budakoglu B, Uncu D,
Ozdemir NY, Guler T, Zengin N. Prognostic factors and clinicopathological
characteristics of carcinoma of ampulla Vateri. Int Surg. 2008
Jul-Aug;93(4):214-9. PubMed PMID: 19731856.
46: Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G,
Zengin N. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP
(cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in
patients with relapsed or refractory lymphoma. Cancer Invest. 2008
May;26(4):401-6. doi: 10.1080/07357900701788098. PubMed PMID: 18443961.
47: Nasiroğlu N, Pamukçuoğlu M, Abali H, Oksüzoğlu B, Uner A, Zengin N. Tamoxifen
induced-thrombocytopenia: it does occur. Med Oncol. 2007;24(4):453-4. PubMed
PMID: 17917098.
48: Pamukçuoglu M, Budakoğlu B, Han O, Tad M, Oksüzoğlu B, Abali H, Zengin N. An
extraordinary case in whom gastrointestinal stromal tumor and low-grade malignant
lymphoma are seen together in the stomach. Med Oncol. 2007;24(3):351-3. PubMed
PMID: 17873313.
49: Elkiran ET, Abali H, Aksoy S, Altundag K, Erman M, Kars A, Turker A, Tekuzman
G, Ozisik Y. Thymic epithelial neoplasia: a study of 58 cases. Med Oncol.
2007;24(2):197-201. PubMed PMID: 17848744.
50: Oksuzoğlu B, Vural M, Abali H, Yilmaz M, Yildirim N, Zengin N. Blood flow
indices by Doppler ultrasonography vary with neoadjuvant chemotherapy but are not
related to plasma VEGF levels in locally advanced breast cancer. Oncology.
2006;71(3-4):185-9. Epub 2007 Jul 18. PubMed PMID: 17641536.
51: Abali H, Celik I. Tropisetron, ondansetron, and granisetron for control of
chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy,
side-effect profile, and cost. Cancer Invest. 2007 Apr-May;25(3):135-9. PubMed
PMID: 17530482.
52: Abali H, Abali G, Aksoy S. Which one is better: AIDS related or HIV
associated? J Clin Oncol. 2007 Feb 20;25(6):e6. PubMed PMID: 17308260.
53: Pamukçuoğlu M, Nasiroğlu N, Yildirim N, Ozçelik O, Oksüzoğlu B, Abali H,
Zengin N. [Sinonasal NK/T-cell lymphoma mimicking Wegener's granulomatosis: a
case report]. Tuberk Toraks. 2006;54(3):277-80. Turkish. PubMed PMID: 17001547.
54: Vural M, Abali H, Oksuzoglu B, Akbulut M. An atypical presentation of thymoma
with diffuse pleural dissemination mimicking mesothelioma. Cancer Invest. 2006
Oct;24(6):615-20. PubMed PMID: 16982467.
56: Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus
replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin
Lab Haematol. 2006 Jun;28(3):211-4. PubMed PMID: 16706940.
57: Oksüzoğlu B, Abali H, Bakar M, Yildirim N, Zengin N. Disclosure of cancer
diagnosis to patients and their relatives in Turkey: views of accompanying
persons and influential factors in reaching those views. Tumori. 2006
Jan-Feb;92(1):62-6. PubMed PMID: 16683385.
58: Budakoglu B, Abali H, Oksüzoglu BC, Aksoy S, Zengin N. Performance status
scales may not correctly predict status of cancer patients with paraplegia.
Cancer Invest. 2006 Mar;24(2):221-2. PubMed PMID: 16537194.
59: Aksoy S, Abali H, Kilickap S, Harputluoglu H, Erman M. Metastatic granular
cell tumor: a case report and review of the literature. Acta Oncol.
2006;45(1):91-4. Review. PubMed PMID: 16464802.
60: Abali H, Eren OO, Dizdar O, Karadağ O, Erman M, Yilmaz A, Uluç K, Erdem I,
Türker A. Posterior leukoencephalopathy after combination chemotherapy in a
patient with lymphoma. Leuk Lymphoma. 2005 Dec;46(12):1825-28. PubMed PMID:
16353314.
61: Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, Bozkurt A.
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of
5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005
Dec;78(6):619-26. PubMed PMID: 16338277.
62: Yildirim N, Oksüzoğlu B, Budakoğlu B, Vural M, Abali H, Uncu D, Zengin N.
Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of
ampulla of Vater: report of 3 cases. Hematology. 2005 Oct;10(5):371-4. PubMed
PMID: 16273723.
63: Budakoglu B, Abali H, Uncu D, Yildirim N, Oksüzoglu B, Zengin N. Good
tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on
chronic hemodialysis. J Chemother. 2005 Aug;17(4):452-3. PubMed PMID: 16167527.
64: Abali H, Oyan B, Guler N. Alprazolam significantly improves the efficacy of
granisetron in the prophylaxis of emesis secondary to moderately emetogenic
chemotherapy in patients with breast cancer. Chemotherapy. 2005 Aug;51(5):280-5.
Epub 2005 Aug 12. PubMed PMID: 16103667.
65: Dikbas O, Altundag K, Abali H, Turker A, Engin H, Sungur A, Baltali E.
Embryonal rhabdomyosarcoma of the larynx. Otolaryngol Head Neck Surg. 2005
Jul;133(1):160-2. PubMed PMID: 16025073.
66: Erman M, Baltali E, Karaoglu A, Abali H, Engin H, Ozisik Y, Guler N, Altundag
K, Tekuzman G, Atahan IL, Onat D, Sayek I. A phase II study on the safety and
efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by
paclitaxel in the adjuvant treatment of breast cancer. Cancer Invest.
2005;23(3):215-21. PubMed PMID: 15945507.
67: Aksoy S, Abali H, Kilickap S, Dinçer M, Erman M. Persistent
myeloproliferative reaction to intrauterine thalidomide exposure. Clin Lab
Haematol. 2005 Jun;27(3):211-2. PubMed PMID: 15938731.
68: Abali H, Oyan B, Koc Y, Kars A, Barista I, Uner A, Turker A, Demirkazik F,
Tekin F, Tekuzman G, Kansu E. IIVP salvage regimen induces high response rates in
patients with relapsed lymphoma before autologous stem cell transplantation. Am J
Clin Oncol. 2005 Jun;28(3):264-9. PubMed PMID: 15923799.
69: Aksoy S, Abali H, Kilickap S, Dinçer M, Erman M. Fludarabine phosphate may be
useful in the treatment of graft-versus-host disease. Med Hypotheses.
2005;64(6):1150-2. PubMed PMID: 15823705.
70: Aksoy S, Abali H, Kiliçkap S, Güler N. Successful treatment of a
chemoresistant tumor with temozolomide in an adult patient: report of a recurrent
intracranial mesenchymal chondrosarcoma. J Neurooncol. 2005 Feb;71(3):333-4.
PubMed PMID: 15735926.
71: Kilickap S, Abali H, Aksoy S, Celik I. Ca 19-9 measurement as a screening:
higher cost, lower survival. J Gastroenterol Hepatol. 2004 Dec;19(12):1428.
PubMed PMID: 15610324.
72: Abali H, Oksuzoglu B, Yildirim N, Budakoglu B. Can effectiveness of
allogeneic transplantation be predicted in advance? Med Hypotheses.
2005;64(2
Uzmana Gönderilen Mesaj
Prof.Dr.Hüseyin ABALI'nın Tavsiye Ettiği Uzmanlar
Özel Uzmanlık ve Çalışma Alanları 
Prof.Dr.Hüseyin ABALI'nın Özgeçmişi
Tavsiye ve Teşekkürler
Daha Yakindan Taniyalim.. Üyemizin Sevdikleri : 
Prof.Dr.Hüseyin ABALI'nın Basılı Kitap ve Yayınları
Üye Oldugu Mesleki Kuruluş ve Organizasyonlar 
Yabancı Dil 
Videoları
